Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
504.00    -1.00 (-0.20%)
Bid:
503.50
Ask:
505.00
Spread: 1.50 (0.298%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Update on Preference Share Reduction Timetable

28 Jul 2022 13:00

RNS Number : 1246U
Tate & Lyle PLC
28 July 2022
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

 

28 July 2022

 

Tate & Lyle PLC

("Tate & Lyle")

 

Update on Timetable forProposed Cancellation and Repayment of 6½ per cent. Cumulative Preference Shares

 

Further to the announcement made on 15 June 2022 in relation to Tate & Lyle's proposed reduction of share capital through the cancellation and repayment of its 6½ per cent. cumulative preference shares (the "Preference Shares" and the "Reduction", respectively), and following approval of the Reduction by Tate & Lyle's shareholders at today's annual general meeting, Tate & Lyle is pleased to provide an updated expected timetable of principal events in relation to the Reduction, as set out below.

As noted previously, as the requisite resolutions in relation to the Reduction have now been passed by Tate & Lyle's shareholders, an application will be made to the High Court for confirmation of the Reduction in order to implement the cancellation of the Preferences Shares. Assuming that the High Court confirms the Reduction and the Reduction becomes effective, repayment of amounts due to holders would then be made. The listing of the Preference Shares on the London Stock Exchange would also be cancelled.

Update on Expected Timetable

Event

Expected time and/or date(1)

Record time and date for entitlement to 3.25 per cent. dividend payable to holders of Preference Shares on 30 September 2022

6.00 p.m. on 2 September 2022

Final High Court hearing to confirm the Reduction

10.30 a.m. on 13 September 2022

Last day of dealings in, and for registration of transfers of, and disablement in CREST of, the Preference Shares

16 September 2022

Repayment record time and date

6.00 p.m. on 16 September 2022

Suspension of trading of Preference Shares 

7.30 a.m. on 19 September 2022

Effective date for the Reduction

Between 19 September 2022and 30 September 2022(2)

Cancellation of listing and trading of Preference Shares

Between 19 September 2022and 30 September 2022(3)

Despatch of cheques and crediting of CREST accounts in respect of the repayment of the Preference Shares and dividends accrued thereon

 

On or around 30 September 2022

(1) The dates and times given are indicative only and are based on current expectations and may be subject to change, including, for example, on the direction of the High Court. References to times are London time, unless otherwise stated. If any of the times and/or dates above change, the revised times and/or dates will be announced via a Regulatory Information Service.

(2) In order for the Reduction to become effective, the High Court order confirming the Reduction must be registered at the Registrar of Companies, which can take a number of days.

(3) It is expected that the cancellation of listing and trading of the Preference Shares will take place shortly after the Reduction has become effective.

Intention to cancel listing and trading of the Preference Shares

As at the close of business on 27 July 2022, Tate & Lyle had in issue 2,394,000 Preference Shares. The Preference Shares are admitted to the standard segment of the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange's main market for listed securities with ISIN number GB0008754466. The terms of the Preference Shares are set out in Tate & Lyle's articles of association.

Tate & Lyle has requested the cancellation of the listing of the Preference Shares from the standard segment of the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange's main market for listed securities. For the purposes of Listing Rule 5.2.8, Tate & Lyle hereby gives at least 20 business days' notice of such intended cancellation in accordance with the expected timetable set out above.

For more information contact:

 

Investors and analysts

Christopher Marsh, VP Investor Relations

Tel - Mobile: +44 (0) 7796 192 688

 

 

Information on Tate & Lyle

 

Tate & Lyle is a leading global provider of food and beverage ingredients and solutions. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

Through our expertise in sweetening, mouthfeel and fibre fortification, we develop solutions which reduce sugar, calories and fat, add fibre, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings.

We have more than 3,500 employees working in around 60 locations across 30 countries. Tate & Lyle's purpose is Transforming Lives Through the Science of Food and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year ended 31 March 2022, Tate & Lyle's revenue from continuing operations totaled £1.4 billion. For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter or LinkedIn.

Tate & Lyle's LEI number is: 2138008K14474WPKZ244

Important notes

 

This announcement is not intended to, and does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation of an offer to purchase, sell, subscribe for or otherwise dispose of or acquire any securities or the solicitation of any vote or approval in any jurisdiction and neither the issue of the information nor anything contained herein shall form the basis of or be relied upon in connection with, or act as an inducement to enter into, any investment activity. No shares are being offered to the public by means of this announcement. This announcement does not constitute either advice or a recommendation regarding any securities, or purport to contain all of the information that may be required to evaluate any investment in Tate & Lyle or any of its securities and should not be relied upon to form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. Past performance is not an indication of future results and past performance should not be taken as a representation that trends or activities underlying past performance will continue in the future.

Shareholders are advised to carefully read the Notice, once available. Any response to the Reduction should be made only on the basis of the information in the Notice. If you are in any doubt as to what action you should take in relation to this announcement or in connection with the Reduction, you are recommended to seek your own personal financial advice immediately from your stockbroker, bank manager, solicitor, accountant or other independent financial adviser authorised under the Financial Services and Markets Act 2000, or from another appropriately authorised independent financial adviser.

The distribution of this announcement in jurisdictions or from certain jurisdictions may be restricted or prohibited by the laws of any jurisdiction other than the United Kingdom. Recipients are required to inform themselves of, and comply with, all restrictions or prohibitions in such other jurisdictions. Any failure to comply with applicable requirements may constitute a violation of the laws and/or regulations of other such jurisdiction.

This announcement has been prepared for the purposes of complying with the applicable law and regulation of the United Kingdom (including the Listing Rules and the Disclosure Guidance and Transparency Rules) and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws and regulations of any jurisdiction outside of the United Kingdom.

This announcement is being distributed to all shareholders in Tate & Lyle. A copy of this announcement can be found on our website at www.tateandlyle.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUWOARUOUBUAR
Date   Source Headline
17th Feb 20222:00 pmRNSHolding(s) in Company
14th Feb 20222:00 pmRNSHolding(s) in Company
11th Feb 20227:00 amRNSTrading Statement
10th Feb 20222:00 pmRNSHolding(s) in Company
9th Feb 20227:00 amRNSDirectorate Change
3rd Feb 20224:00 pmRNSHolding(s) in Company
1st Feb 20223:30 pmRNSHolding(s) in Company
21st Jan 20222:00 pmRNSHolding(s) in Company
17th Jan 20222:00 pmRNSHolding(s) in Company
12th Jan 20224:00 pmRNSHolding(s) in Company
10th Jan 20223:45 pmRNSChange of Registered Office
10th Jan 20223:40 pmRNSDirector/PDMR Shareholding
4th Jan 20224:00 pmRNSBlock listing Interim Review
10th Dec 20212:09 pmRNSHolding(s) in Company
9th Dec 20213:10 pmRNSDirector/PDMR Shareholding
1st Dec 20219:58 amRNSTotal Voting Rights
18th Nov 20214:15 pmRNSHolding(s) in Company
5th Nov 202111:45 amRNSDirector/PDMR Shareholding
4th Nov 20217:00 amRNSHalf-year Report
3rd Nov 20216:01 pmRNSDirectorate Change
29th Oct 202111:15 amRNSHolding(s) in Company
21st Oct 20214:45 pmRNSRestatement re Primary Products Disposal
18th Oct 20212:30 pmRNSHolding(s) in Company
13th Oct 202112:30 pmRNSHolding(s) in Company
6th Oct 20213:30 pmRNSHolding(s) in Company
6th Oct 202111:15 amRNSDirector/PDMR Shareholding
4th Oct 20212:30 pmRNSDirector/PDMR Shareholding
4th Oct 20217:00 amRNSTotal Voting Rights
30th Sep 202112:00 pmRNSResult of General Meeting
13th Sep 20214:30 pmRNSCircular re. KPS Partnership
1st Sep 20219:58 amRNSTotal Voting Rights
18th Aug 202110:10 amRNSDirector/PDMR Shareholding
11th Aug 20214:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20213:15 pmRNSTotal Voting Rights
29th Jul 202112:45 pmRNSResult of AGM
23rd Jul 20215:00 pmRNSHolding(s) in Company
22nd Jul 20213:15 pmRNSDirector/PDMR Shareholding
16th Jul 20213:30 pmRNSHolding(s) in Company
12th Jul 20214:00 pmRNSHolding(s) in Company
12th Jul 20213:50 pmRNSHolding(s) in Company
12th Jul 20217:00 amRNSTate & Lyle to be re-positioned as growth business
8th Jul 20213:30 pmRNSHolding(s) in Company
8th Jul 20213:14 pmRNSHolding(s) in Company
1st Jul 20214:40 pmRNSBlock listing Interim Review
1st Jul 20214:38 pmRNSTotal Voting Rights
15th Jun 20212:15 pmRNSAnnual Financial Report
14th Jun 20212:05 pmRNSHolding(s) in Company
14th Jun 20212:00 pmRNSHolding(s) in Company
9th Jun 20213:49 pmRNSDirector/PDMR Shareholding
1st Jun 20212:34 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.